Synaptics (NASDAQ:SYNA) reported fiscal second-quarter 2026 results that management described as another “solid quarter,” ...
Leads Biolabs is developing LBL-047, a new bispecific antibody for autoimmune diseases that targets B cells and pDCs. LBL-047 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results